Using molecular symmetry to form new drugs: hydroxymethyl-substituted 3,9-diazatetraasteranes as the first class of symmetric MDR modulators.
Hilgeroth
Andreas
A
Martin-Luther-Universität Institut für Pharmazeutische Chemie Wolfgang-Langenbeck-Strasse 4 06120 Halle, Germany. hilgeroth@pharmazie.uni-halle.de
Molnár
Jósef
J
De Clercq
Eric
E
D018435:ATP Binding Cassette Transporter, Subfamily B / Q000037:antagonists & inhibitors / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D015195:Drug Design; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D006571:Heterocyclic Compounds / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D051379:Mice; D015394:Molecular Structure; D014407:Tumor Cells, Cultured
D018435:ATP Binding Cassette Transporter, Subfamily B; D000970:Antineoplastic Agents; D006571:Heterocyclic Compounds